# Elicio Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Elicio Therapeutics, Inc.). ## Overview Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapy product candidates for cancer, with its lead program ELI-002 7P aimed at mKRAS-driven tumors. The company does not yet have approved products or product revenue and is still centered on research, clinical development, and intellectual property protection. ## Products & services • ELI-002 7P lead cancer immunotherapy candidate • Preclinical oncology programs advancing toward clinical trials • AMP platform technology for immune-targeted therapies • mKRAS-driven cancer program • Mutant BRAF-driven cancer program • Mutant TP53-expressing cancer program - **Clinical-stage oncology immunotherapy** (0%) — Lead and pipeline therapeutic candidates designed to treat cancer through immune-based mechanisms. - **Preclinical drug discovery** (0%) — Early-stage programs and discovery work intended to generate future clinical candidates. - **Platform technology licensing and development** (0%) — AMP platform and related intellectual property used to support internal development and potential partnering. - **Collaboration and licensing arrangements** (0%) — Potential non-product revenue sources such as partnerships, licenses, or similar strategic deals. - **Research and development services** (0%) — Internal and outsourced R&D activities supporting clinical and preclinical advancement. - ELI-002 7P lead cancer immunotherapy candidate - Preclinical oncology programs advancing toward clinical trials - AMP platform technology for immune-targeted therapies - mKRAS-driven cancer program - Mutant BRAF-driven cancer program - Mutant TP53-expressing cancer program ## Customers Elicio does not currently sell approved products, so its near-term counterparties are primarily clinical investigators, contract research organizations, manufacturers, and potential licensing partners rather than end-market patients. If its programs succeed, future customers would include oncology physicians, hospitals, and payors that adopt the approved therapies. The company’s commercial opportunity is therefore still dependent on regulatory success and on whether partners or healthcare systems see clinical and reimbursement value. - **Clinical development partners** (primary) — Investigators, CROs, and CMOs that execute trials, manufacture materials, and support regulatory development. - **Strategic licensing partners** (primary) — Biopharma companies that may license or collaborate on the AMP platform or pipeline assets. - **Future oncology providers** (secondary) — Hospitals and oncology physicians that would prescribe the therapy if approved and clinically adopted. - **Future payors** (secondary) — Government and private payors that would determine coverage and reimbursement after approval. - Clinical investigators and trial sites running Elicio studies - CROs and CMOs supporting development and manufacturing - Potential pharma partners for licensing or collaboration - Future oncology physicians and hospitals if products are approved - Future payors and health systems that would determine reimbursement ## Geography Elicio is headquartered in Boston, Massachusetts, and operates as a U.S.-based clinical-stage biotech company. It also has an Australian subsidiary established to support research credit qualification for studies conducted in Australia. The company’s disclosed risk profile highlights reliance on foreign and foreign-owned vendors for certain clinical and discovery activities, which creates supply-chain and regulatory exposure. - Headquartered in Boston, Massachusetts, United States - Australian subsidiary supports research-credit eligible studies - Clinical and discovery work may use foreign vendors and services - No approved products, so no disclosed revenue geography yet ## Strategy Elicio’s strategy is to advance ELI-002 7P into late-stage clinical trials, move preclinical programs into the clinic, and broaden its pipeline around its AMP platform. It also aims to protect its intellectual property, pursue regulatory approvals, and potentially supplement internal development through acquisitions or in-licensing. Because it has no approved products, execution is mainly about converting scientific assets into clinical and regulatory milestones while preserving cash runway. - **Advance ELI-002 7P through late-stage development** (short-term) — The lead asset is the main value driver and the clearest path to clinical and regulatory validation. - **Broaden the pipeline from preclinical to clinical** (medium-term) — A deeper pipeline reduces single-asset dependence and improves long-term partnering optionality. - **Protect intellectual property and platform value** (long-term) — Patent coverage is central to differentiation, partnering leverage, and eventual commercialization. - Advance ELI-002 7P into late-stage clinical trials - Move preclinical programs into clinical development - Expand the pipeline around the AMP platform - Seek regulatory approval for investigational medicines - Protect and defend the patent portfolio - Use partnerships or in-licensing to extend the platform ## Risks Elicio faces the classic risks of a clinical-stage biotech: it has no approved products, recurring losses, and a need for substantial additional capital, with management disclosing substantial doubt about going concern. Development, regulatory, manufacturing, and reimbursement outcomes are uncertain, and any delay or failure can materially impair value. The company also depends on patent protection and third-party vendors, including foreign suppliers, which adds IP, supply-chain, and regulatory risk. - **Financing and going concern risk** [critical] — The company has recurring operating losses and will need additional capital to fund development beyond its current runway. - **Clinical and regulatory failure** [high] — Pipeline value depends on successful trial outcomes and FDA/foreign regulatory approvals, which are inherently uncertain. - **Intellectual property protection** [high] — The company’s competitive position relies on patents for the AMP platform and specific cancer programs. - **Third-party manufacturing and vendor dependence** [medium] — Clinical materials and services are outsourced, so vendor noncompliance or disruption can delay development. - **Reimbursement and commercialization uncertainty** [medium] — Even if approved, payor coverage and pricing pressure may limit adoption and economics. - No approved products, so value depends on clinical and regulatory success - Substantial additional capital is needed and financing may be dilutive - Going concern risk from recurring losses and limited cash runway - Patent protection may be incomplete or challenged by competitors - CMO/vendor compliance failures could delay trials or product approval - Foreign vendor reliance adds supply-chain and trade restriction exposure ## Accounting The most important accounting issue is the estimation of accrued research and development costs, because trial, manufacturing, and consultant expenses often arrive after the service period and must be estimated. As a pre-revenue biotech, Elicio also depends heavily on fair-value and judgment-based accounting for equity-based compensation, contingent obligations, and any future collaboration or licensing arrangements. Its going-concern disclosure and cash runway assumptions are especially important because they influence how investors assess liquidity and the need for future financing. - **Accrued research and development costs** — Can shift operating expenses between quarters and affect comparability - **Going concern assessment** — Important for liquidity analysis and financing assumptions - **Equity-based compensation** — Affects reported operating loss and share-based dilution analysis - **Collaboration and license accounting** — Could materially affect revenue recognition timing if deals are signed - Accrued R&D costs affect timing of clinical and vendor expenses - Equity-based compensation can materially affect operating expenses - Going concern assessment reflects cash runway and financing needs - Future collaboration or license accounting may affect revenue timing - No product revenue yet, so expense recognition dominates results --- *Last updated: 2026-04-28T20:04:34.266635+00:00*